| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Baroreflex | 29 | 2019 | 84 | 7.470 |
Why?
|
| Peptide Fragments | 63 | 2019 | 422 | 7.300 |
Why?
|
| Angiotensin I | 67 | 2019 | 262 | 6.990 |
Why?
|
| Renin-Angiotensin System | 36 | 2019 | 182 | 5.370 |
Why?
|
| Blood Pressure | 67 | 2019 | 806 | 5.030 |
Why?
|
| Angiotensin II | 80 | 2018 | 279 | 4.890 |
Why?
|
| Hypertension | 35 | 2019 | 910 | 4.470 |
Why?
|
| Solitary Nucleus | 17 | 2015 | 34 | 4.250 |
Why?
|
| Heart Rate | 43 | 2019 | 315 | 3.650 |
Why?
|
| Renin | 14 | 2019 | 112 | 3.200 |
Why?
|
| Receptor, Angiotensin, Type 1 | 23 | 2017 | 75 | 3.180 |
Why?
|
| Medulla Oblongata | 24 | 2019 | 53 | 3.020 |
Why?
|
| Rats | 84 | 2017 | 1604 | 2.870 |
Why?
|
| Receptors, Angiotensin | 38 | 2013 | 77 | 2.850 |
Why?
|
| Animals | 141 | 2019 | 7299 | 2.750 |
Why?
|
| Brain | 20 | 2019 | 930 | 2.660 |
Why?
|
| Aging | 15 | 2015 | 881 | 2.380 |
Why?
|
| Betamethasone | 9 | 2019 | 52 | 2.350 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 17 | 2012 | 134 | 2.300 |
Why?
|
| Antihypertensive Agents | 13 | 2019 | 342 | 2.290 |
Why?
|
| Angiotensinogen | 14 | 2012 | 73 | 2.280 |
Why?
|
| Prenatal Exposure Delayed Effects | 10 | 2019 | 88 | 2.270 |
Why?
|
| Heart | 9 | 2019 | 162 | 2.220 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 12 | 2019 | 68 | 2.170 |
Why?
|
| Angiotensins | 14 | 2018 | 49 | 2.070 |
Why?
|
| Vagus Nerve | 11 | 2019 | 29 | 2.030 |
Why?
|
| Tetrazoles | 21 | 2019 | 71 | 1.980 |
Why?
|
| Kidney | 21 | 2019 | 486 | 1.760 |
Why?
|
| Rats, Sprague-Dawley | 28 | 2015 | 747 | 1.590 |
Why?
|
| Autonomic Nervous System | 6 | 2019 | 42 | 1.570 |
Why?
|
| Sympathetic Nervous System | 6 | 2019 | 29 | 1.460 |
Why?
|
| Peptidyl-Dipeptidase A | 17 | 2014 | 142 | 1.450 |
Why?
|
| Male | 104 | 2019 | 17815 | 1.390 |
Why?
|
| Benzimidazoles | 9 | 2019 | 33 | 1.330 |
Why?
|
| Leptin | 8 | 2014 | 66 | 1.290 |
Why?
|
| Neuroglia | 4 | 2012 | 29 | 1.110 |
Why?
|
| Glucocorticoids | 8 | 2019 | 149 | 1.110 |
Why?
|
| Imidazoles | 17 | 2017 | 104 | 1.100 |
Why?
|
| Catecholamines | 2 | 2015 | 17 | 1.060 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 2 | 2015 | 8 | 1.050 |
Why?
|
| Rats, Transgenic | 9 | 2019 | 52 | 0.990 |
Why?
|
| Vasopressins | 5 | 2018 | 17 | 0.890 |
Why?
|
| Nitric Oxide | 7 | 2017 | 116 | 0.890 |
Why?
|
| Nausea | 4 | 2018 | 49 | 0.880 |
Why?
|
| Pregnancy | 19 | 2019 | 815 | 0.820 |
Why?
|
| Endocannabinoids | 3 | 2015 | 34 | 0.800 |
Why?
|
| Receptors, G-Protein-Coupled | 5 | 2019 | 89 | 0.780 |
Why?
|
| Piperidines | 3 | 2019 | 125 | 0.780 |
Why?
|
| Neurotransmitter Agents | 4 | 2010 | 26 | 0.770 |
Why?
|
| Oxidative Stress | 5 | 2019 | 223 | 0.760 |
Why?
|
| RNA, Messenger | 15 | 2015 | 514 | 0.730 |
Why?
|
| Mesenteric Arteries | 4 | 2013 | 18 | 0.730 |
Why?
|
| Radiation Injuries | 3 | 2010 | 67 | 0.710 |
Why?
|
| Rats, Inbred SHR | 12 | 2011 | 42 | 0.710 |
Why?
|
| Orthostatic Intolerance | 5 | 2019 | 10 | 0.710 |
Why?
|
| Gene Expression Regulation | 6 | 2015 | 481 | 0.690 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 11 | 0.690 |
Why?
|
| Disease Models, Animal | 10 | 2019 | 980 | 0.690 |
Why?
|
| Organophosphorus Compounds | 1 | 2019 | 35 | 0.680 |
Why?
|
| Calcium Signaling | 3 | 2015 | 40 | 0.660 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2019 | 90 | 0.650 |
Why?
|
| Substance P | 7 | 2002 | 22 | 0.630 |
Why?
|
| Receptors, Calcium-Sensing | 3 | 2013 | 10 | 0.620 |
Why?
|
| Fludrocortisone | 2 | 2014 | 5 | 0.610 |
Why?
|
| Sheep | 14 | 2018 | 221 | 0.610 |
Why?
|
| Animals, Genetically Modified | 11 | 2008 | 67 | 0.590 |
Why?
|
| Aldosterone | 2 | 2015 | 28 | 0.580 |
Why?
|
| Captopril | 3 | 2011 | 8 | 0.560 |
Why?
|
| Reactive Oxygen Species | 7 | 2019 | 159 | 0.560 |
Why?
|
| Hypotension, Orthostatic | 1 | 2015 | 10 | 0.550 |
Why?
|
| Cardiovascular Physiological Phenomena | 5 | 2017 | 15 | 0.540 |
Why?
|
| Dual Specificity Phosphatase 1 | 2 | 2012 | 29 | 0.540 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2012 | 18 | 0.540 |
Why?
|
| Syncope | 1 | 2015 | 24 | 0.540 |
Why?
|
| Enzyme Inhibitors | 6 | 2013 | 162 | 0.540 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2010 | 51 | 0.530 |
Why?
|
| Vasoconstrictor Agents | 8 | 2014 | 62 | 0.520 |
Why?
|
| Female | 37 | 2019 | 18173 | 0.510 |
Why?
|
| Cardiomegaly | 1 | 2014 | 30 | 0.510 |
Why?
|
| Hypothalamus | 8 | 1997 | 18 | 0.510 |
Why?
|
| Mineralocorticoids | 1 | 2014 | 4 | 0.500 |
Why?
|
| Stomach Diseases | 1 | 2014 | 7 | 0.500 |
Why?
|
| Cardiovascular System | 6 | 2019 | 39 | 0.500 |
Why?
|
| Abdominal Pain | 1 | 2014 | 40 | 0.490 |
Why?
|
| Receptor, Angiotensin, Type 2 | 9 | 2016 | 23 | 0.480 |
Why?
|
| Premature Birth | 4 | 2019 | 39 | 0.480 |
Why?
|
| Arachidonic Acids | 3 | 2015 | 23 | 0.480 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2013 | 37 | 0.480 |
Why?
|
| Phenylephrine | 8 | 2017 | 27 | 0.480 |
Why?
|
| NG-Nitroarginine Methyl Ester | 5 | 2017 | 18 | 0.470 |
Why?
|
| Microinjections | 7 | 2015 | 33 | 0.470 |
Why?
|
| Tilt-Table Test | 4 | 2018 | 13 | 0.460 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 17 | 0.460 |
Why?
|
| Humans | 50 | 2019 | 29123 | 0.460 |
Why?
|
| Time Factors | 14 | 2015 | 2001 | 0.440 |
Why?
|
| Vasodilation | 8 | 2017 | 87 | 0.440 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2011 | 19 | 0.440 |
Why?
|
| Stress, Physiological | 1 | 2012 | 44 | 0.430 |
Why?
|
| Nerve Net | 1 | 2013 | 115 | 0.420 |
Why?
|
| Kidney Medulla | 2 | 2011 | 29 | 0.410 |
Why?
|
| Subfornical Organ | 3 | 2016 | 4 | 0.410 |
Why?
|
| Mediodorsal Thalamic Nucleus | 1 | 2011 | 5 | 0.400 |
Why?
|
| Hydralazine | 1 | 2011 | 8 | 0.400 |
Why?
|
| Cardiovascular Diseases | 5 | 2018 | 1017 | 0.400 |
Why?
|
| Hydronephrosis | 1 | 2011 | 12 | 0.400 |
Why?
|
| Signal Transduction | 10 | 2019 | 666 | 0.400 |
Why?
|
| Insulin | 6 | 2014 | 346 | 0.390 |
Why?
|
| Mice | 10 | 2016 | 2370 | 0.390 |
Why?
|
| Pre-Eclampsia | 4 | 2014 | 53 | 0.380 |
Why?
|
| Down-Regulation | 6 | 2013 | 143 | 0.380 |
Why?
|
| Losartan | 17 | 2017 | 69 | 0.370 |
Why?
|
| Brain Injuries | 1 | 2010 | 94 | 0.360 |
Why?
|
| Adolescent | 12 | 2019 | 3255 | 0.360 |
Why?
|
| Muscle, Smooth, Vascular | 9 | 2013 | 71 | 0.360 |
Why?
|
| Neprilysin | 8 | 2013 | 32 | 0.360 |
Why?
|
| Body Weight | 8 | 2012 | 290 | 0.350 |
Why?
|
| Leucine | 2 | 2009 | 24 | 0.350 |
Why?
|
| Fetal Development | 3 | 2018 | 25 | 0.350 |
Why?
|
| Behavior, Animal | 1 | 2011 | 264 | 0.350 |
Why?
|
| Immunoglobulin G | 2 | 2009 | 104 | 0.340 |
Why?
|
| Vasoconstriction | 5 | 2013 | 40 | 0.340 |
Why?
|
| Brain Chemistry | 3 | 2006 | 30 | 0.340 |
Why?
|
| Pyridines | 8 | 2017 | 78 | 0.330 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 29 | 0.330 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 3 | 2004 | 8 | 0.320 |
Why?
|
| Hypertension, Renal | 2 | 2007 | 29 | 0.310 |
Why?
|
| Biphenyl Compounds | 7 | 2001 | 19 | 0.310 |
Why?
|
| Metabolism | 1 | 2007 | 7 | 0.310 |
Why?
|
| Rats, Inbred WKY | 7 | 2010 | 24 | 0.310 |
Why?
|
| Oligopeptides | 10 | 2014 | 51 | 0.300 |
Why?
|
| Autoradiography | 12 | 2009 | 47 | 0.300 |
Why?
|
| Sex Factors | 5 | 2019 | 631 | 0.290 |
Why?
|
| Hypotension | 3 | 2015 | 47 | 0.280 |
Why?
|
| Genetic Techniques | 1 | 2006 | 7 | 0.280 |
Why?
|
| Rats, Inbred F344 | 7 | 2012 | 125 | 0.280 |
Why?
|
| Diabetic Angiopathies | 1 | 2007 | 137 | 0.280 |
Why?
|
| Child | 7 | 2019 | 2219 | 0.280 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2007 | 136 | 0.280 |
Why?
|
| Calcium | 7 | 2015 | 297 | 0.270 |
Why?
|
| Renal Circulation | 2 | 2007 | 13 | 0.270 |
Why?
|
| Diabetic Nephropathies | 1 | 2007 | 195 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2012 | 641 | 0.270 |
Why?
|
| Fetus | 3 | 2019 | 78 | 0.270 |
Why?
|
| Hemodynamics | 4 | 2014 | 148 | 0.270 |
Why?
|
| Proteinuria | 4 | 2011 | 57 | 0.270 |
Why?
|
| Rats, Inbred Strains | 16 | 2006 | 45 | 0.260 |
Why?
|
| Prostaglandins | 8 | 2000 | 17 | 0.260 |
Why?
|
| Pressoreceptors | 4 | 2000 | 6 | 0.260 |
Why?
|
| Insulin Resistance | 2 | 2014 | 449 | 0.260 |
Why?
|
| Cranial Irradiation | 3 | 2012 | 84 | 0.260 |
Why?
|
| Placenta | 4 | 2019 | 63 | 0.250 |
Why?
|
| Mitochondria | 2 | 2019 | 174 | 0.250 |
Why?
|
| Reference Values | 4 | 2010 | 224 | 0.250 |
Why?
|
| Analysis of Variance | 6 | 2014 | 454 | 0.250 |
Why?
|
| Ganglia, Sympathetic | 1 | 2004 | 1 | 0.240 |
Why?
|
| Gene Expression | 5 | 2013 | 332 | 0.240 |
Why?
|
| Infant, Premature | 3 | 2018 | 62 | 0.240 |
Why?
|
| Enalapril | 3 | 2012 | 7 | 0.240 |
Why?
|
| Bradykinin | 5 | 2014 | 18 | 0.230 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 32 | 0.230 |
Why?
|
| Age Factors | 6 | 2019 | 1108 | 0.230 |
Why?
|
| Blood Glucose | 4 | 2011 | 466 | 0.220 |
Why?
|
| Thiazepines | 1 | 2002 | 3 | 0.220 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 113 | 0.220 |
Why?
|
| Glycerides | 2 | 2015 | 13 | 0.210 |
Why?
|
| Adaptation, Physiological | 2 | 2012 | 51 | 0.210 |
Why?
|
| Protein Kinase C-alpha | 2 | 2015 | 6 | 0.210 |
Why?
|
| Kidney Cortex | 5 | 2010 | 25 | 0.210 |
Why?
|
| Cognition Disorders | 3 | 2012 | 390 | 0.210 |
Why?
|
| Random Allocation | 4 | 2010 | 213 | 0.210 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 5 | 0.200 |
Why?
|
| Reflex | 4 | 2014 | 15 | 0.200 |
Why?
|
| Vasodilator Agents | 4 | 2013 | 54 | 0.200 |
Why?
|
| Bradycardia | 2 | 2012 | 15 | 0.200 |
Why?
|
| Uterus | 2 | 2013 | 73 | 0.190 |
Why?
|
| Neural Pathways | 2 | 2000 | 97 | 0.190 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2012 | 33 | 0.190 |
Why?
|
| Systole | 3 | 2015 | 87 | 0.190 |
Why?
|
| Ischemia | 1 | 2000 | 92 | 0.180 |
Why?
|
| Up-Regulation | 3 | 2019 | 183 | 0.180 |
Why?
|
| Rats, Wistar | 4 | 2008 | 84 | 0.180 |
Why?
|
| Inositol | 1 | 2019 | 5 | 0.180 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2010 | 39 | 0.180 |
Why?
|
| Choline | 1 | 2019 | 14 | 0.180 |
Why?
|
| Mice, Knockout | 3 | 2016 | 425 | 0.180 |
Why?
|
| Injections | 2 | 2012 | 61 | 0.170 |
Why?
|
| Dehydration | 1 | 1999 | 7 | 0.170 |
Why?
|
| Renal Artery | 2 | 2017 | 43 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2019 | 86 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 101 | 0.170 |
Why?
|
| PPAR gamma | 2 | 2010 | 45 | 0.170 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 118 | 0.160 |
Why?
|
| Blotting, Western | 4 | 2012 | 281 | 0.160 |
Why?
|
| Brain Stem | 2 | 2009 | 18 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 532 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 248 | 0.160 |
Why?
|
| Sheep, Domestic | 2 | 2019 | 18 | 0.160 |
Why?
|
| Infant, Newborn | 5 | 2018 | 599 | 0.160 |
Why?
|
| Obesity | 2 | 2015 | 1063 | 0.160 |
Why?
|
| Physiology | 1 | 2017 | 1 | 0.160 |
Why?
|
| Phosphorylation | 3 | 2015 | 225 | 0.150 |
Why?
|
| Diuresis | 3 | 2006 | 9 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2019 | 37 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 863 | 0.150 |
Why?
|
| Receptors, Bradykinin | 1 | 2017 | 3 | 0.150 |
Why?
|
| Nitrates | 1 | 2017 | 25 | 0.150 |
Why?
|
| Hemoglobins | 2 | 2014 | 42 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2015 | 65 | 0.150 |
Why?
|
| Prosencephalon | 1 | 1996 | 5 | 0.150 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2015 | 51 | 0.150 |
Why?
|
| Overweight | 1 | 2018 | 256 | 0.140 |
Why?
|
| Myocardium | 2 | 2008 | 170 | 0.140 |
Why?
|
| Perfusion | 2 | 2011 | 64 | 0.140 |
Why?
|
| Chronic Disease | 2 | 2014 | 370 | 0.140 |
Why?
|
| Preoptic Area | 4 | 1999 | 5 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 95 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2017 | 170 | 0.140 |
Why?
|
| Epinephrine | 1 | 2015 | 41 | 0.140 |
Why?
|
| Pertussis Toxin | 1 | 2015 | 16 | 0.140 |
Why?
|
| Rats, Inbred Lew | 3 | 2011 | 116 | 0.130 |
Why?
|
| Diastole | 1 | 2015 | 90 | 0.130 |
Why?
|
| Norepinephrine | 1 | 2015 | 73 | 0.130 |
Why?
|
| Neuroblastoma | 1 | 2015 | 32 | 0.130 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2015 | 16 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 148 | 0.130 |
Why?
|
| Spinal Cord Injuries | 1 | 2015 | 32 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2015 | 61 | 0.130 |
Why?
|
| Vascular Resistance | 2 | 2013 | 28 | 0.130 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 99 | 0.130 |
Why?
|
| Receptors, Leptin | 1 | 2014 | 6 | 0.130 |
Why?
|
| Resistance Training | 1 | 2015 | 70 | 0.130 |
Why?
|
| Iodine Radioisotopes | 4 | 2006 | 18 | 0.130 |
Why?
|
| Exercise | 2 | 2017 | 592 | 0.130 |
Why?
|
| Community Health Centers | 1 | 2014 | 13 | 0.130 |
Why?
|
| Carboxypeptidases | 2 | 2005 | 20 | 0.130 |
Why?
|
| Craniocerebral Trauma | 1 | 2015 | 56 | 0.130 |
Why?
|
| Erythrocytes | 1 | 2014 | 43 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2015 | 91 | 0.130 |
Why?
|
| Antioxidants | 2 | 2012 | 114 | 0.130 |
Why?
|
| Glutamic Acid | 2 | 2010 | 46 | 0.130 |
Why?
|
| Caloric Restriction | 1 | 2015 | 92 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2018 | 2021 | 0.120 |
Why?
|
| Gestational Age | 4 | 2019 | 96 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2014 | 54 | 0.120 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 250 | 0.120 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 519 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2019 | 126 | 0.120 |
Why?
|
| Choroid Plexus | 1 | 2013 | 3 | 0.120 |
Why?
|
| Ouabain | 1 | 2013 | 5 | 0.120 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2012 | 30 | 0.120 |
Why?
|
| Body Mass Index | 4 | 2018 | 865 | 0.120 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2011 | 11 | 0.120 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2013 | 27 | 0.120 |
Why?
|
| Dogs | 9 | 2000 | 117 | 0.120 |
Why?
|
| Mothers | 1 | 2014 | 79 | 0.110 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 49 | 0.110 |
Why?
|
| Infant, Very Low Birth Weight | 3 | 2018 | 47 | 0.110 |
Why?
|
| Reperfusion Injury | 2 | 2006 | 43 | 0.110 |
Why?
|
| Dopamine | 1 | 2015 | 226 | 0.110 |
Why?
|
| Cyclic N-Oxides | 1 | 2012 | 8 | 0.110 |
Why?
|
| Spin Labels | 1 | 2012 | 23 | 0.110 |
Why?
|
| Anxiety | 1 | 2014 | 159 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 1 | 2012 | 13 | 0.110 |
Why?
|
| Animals, Newborn | 2 | 2012 | 111 | 0.110 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 13 | 0.110 |
Why?
|
| Homeostasis | 3 | 2019 | 127 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 711 | 0.110 |
Why?
|
| Ion Channels | 1 | 2012 | 24 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 37 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 44 | 0.110 |
Why?
|
| Ramipril | 1 | 2012 | 4 | 0.110 |
Why?
|
| Tachycardia | 1 | 2012 | 3 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2011 | 274 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 69 | 0.110 |
Why?
|
| Cell Nucleus | 2 | 2010 | 105 | 0.110 |
Why?
|
| Drinking | 2 | 2009 | 10 | 0.100 |
Why?
|
| Chromones | 1 | 2011 | 6 | 0.100 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 67 | 0.100 |
Why?
|
| Androstadienes | 1 | 2011 | 17 | 0.100 |
Why?
|
| Morpholines | 1 | 2011 | 34 | 0.100 |
Why?
|
| Lung | 2 | 2006 | 233 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2014 | 327 | 0.100 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2011 | 5 | 0.100 |
Why?
|
| Heart Failure | 1 | 2017 | 571 | 0.100 |
Why?
|
| Animals, Suckling | 1 | 2011 | 4 | 0.100 |
Why?
|
| Sucking Behavior | 1 | 2011 | 4 | 0.100 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2011 | 22 | 0.100 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2011 | 34 | 0.100 |
Why?
|
| Energy Metabolism | 1 | 2012 | 139 | 0.100 |
Why?
|
| Anesthesia | 1 | 2011 | 65 | 0.100 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 55 | 0.100 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 141 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 57 | 0.100 |
Why?
|
| Hyperglycemia | 2 | 2010 | 82 | 0.100 |
Why?
|
| Hydrocortisone | 1 | 2011 | 61 | 0.100 |
Why?
|
| Pancreas | 3 | 2001 | 79 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 90 | 0.100 |
Why?
|
| Catalase | 1 | 2010 | 16 | 0.090 |
Why?
|
| Nodose Ganglion | 2 | 1988 | 2 | 0.090 |
Why?
|
| Inflammation | 3 | 2014 | 507 | 0.090 |
Why?
|
| Neurochemistry | 1 | 2010 | 3 | 0.090 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1989 | 10 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 81 | 0.090 |
Why?
|
| Cytokines | 1 | 2011 | 243 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 195 | 0.090 |
Why?
|
| Osmolar Concentration | 1 | 2009 | 17 | 0.090 |
Why?
|
| Probability | 1 | 2009 | 150 | 0.090 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2009 | 7 | 0.090 |
Why?
|
| Endothelium, Vascular | 3 | 2013 | 145 | 0.090 |
Why?
|
| Urodynamics | 1 | 2009 | 34 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2010 | 94 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2007 | 83 | 0.090 |
Why?
|
| Cells, Cultured | 8 | 2015 | 799 | 0.080 |
Why?
|
| Astrocytes | 3 | 1996 | 49 | 0.080 |
Why?
|
| Eating | 1 | 2009 | 73 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2008 | 75 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 71 | 0.080 |
Why?
|
| Biguanides | 1 | 2008 | 3 | 0.080 |
Why?
|
| Membranes | 1 | 2008 | 11 | 0.080 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 28 | 0.080 |
Why?
|
| Chorionic Villi | 1 | 2008 | 7 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 273 | 0.080 |
Why?
|
| Cerebral Ventricles | 2 | 1985 | 11 | 0.080 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1984 | 2 | 0.080 |
Why?
|
| Neurons | 3 | 2006 | 394 | 0.080 |
Why?
|
| Body Temperature | 2 | 1984 | 22 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 494 | 0.080 |
Why?
|
| Aged | 4 | 2017 | 9492 | 0.080 |
Why?
|
| Dinoprostone | 6 | 1993 | 37 | 0.080 |
Why?
|
| Protein Binding | 2 | 2009 | 199 | 0.080 |
Why?
|
| Streptozocin | 1 | 2007 | 8 | 0.070 |
Why?
|
| Afferent Pathways | 1 | 1987 | 23 | 0.070 |
Why?
|
| Neuropeptides | 1 | 1987 | 19 | 0.070 |
Why?
|
| Radioligand Assay | 2 | 2010 | 23 | 0.070 |
Why?
|
| Cardiotonic Agents | 1 | 2007 | 39 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 47 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2019 | 859 | 0.070 |
Why?
|
| Connective Tissue Cells | 1 | 2006 | 1 | 0.070 |
Why?
|
| Ganglia, Spinal | 1 | 2007 | 63 | 0.070 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2006 | 8 | 0.070 |
Why?
|
| Species Specificity | 2 | 2004 | 84 | 0.070 |
Why?
|
| Nitrites | 2 | 2017 | 20 | 0.070 |
Why?
|
| Radiation Pneumonitis | 1 | 2006 | 4 | 0.070 |
Why?
|
| NADP | 1 | 2006 | 9 | 0.070 |
Why?
|
| Vasomotor System | 1 | 2006 | 15 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2019 | 469 | 0.070 |
Why?
|
| Lisinopril | 3 | 2005 | 28 | 0.070 |
Why?
|
| Tail | 1 | 2005 | 6 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2005 | 49 | 0.070 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2005 | 9 | 0.070 |
Why?
|
| Epoprostenol | 4 | 1993 | 9 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 109 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 83 | 0.070 |
Why?
|
| Kinins | 1 | 1985 | 1 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 587 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2006 | 190 | 0.060 |
Why?
|
| Models, Animal | 1 | 2005 | 160 | 0.060 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2001 | 5 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1362 | 0.060 |
Why?
|
| Hypothalamus, Anterior | 1 | 1984 | 1 | 0.060 |
Why?
|
| Survivors | 1 | 2006 | 145 | 0.060 |
Why?
|
| Rats, Mutant Strains | 1 | 2004 | 5 | 0.060 |
Why?
|
| Physical Conditioning, Animal | 1 | 2004 | 32 | 0.060 |
Why?
|
| Narcotics | 1 | 1984 | 18 | 0.060 |
Why?
|
| Substrate Specificity | 2 | 2014 | 84 | 0.060 |
Why?
|
| Sodium | 2 | 2003 | 37 | 0.060 |
Why?
|
| Myometrium | 2 | 2013 | 11 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2000 | 39 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2004 | 81 | 0.060 |
Why?
|
| North Carolina | 2 | 2018 | 1423 | 0.060 |
Why?
|
| Cognition | 1 | 2007 | 526 | 0.060 |
Why?
|
| Chemoreceptor Cells | 1 | 2002 | 3 | 0.050 |
Why?
|
| Body Composition | 1 | 2004 | 365 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2014 | 66 | 0.050 |
Why?
|
| Adrenalectomy | 3 | 1989 | 29 | 0.050 |
Why?
|
| Inositol Phosphates | 1 | 2001 | 2 | 0.050 |
Why?
|
| CHO Cells | 1 | 2001 | 25 | 0.050 |
Why?
|
| Receptors, Thromboxane | 1 | 2001 | 1 | 0.050 |
Why?
|
| Cricetinae | 1 | 2001 | 58 | 0.050 |
Why?
|
| Injections, Intraventricular | 3 | 2005 | 16 | 0.050 |
Why?
|
| Enzymes | 1 | 2000 | 5 | 0.050 |
Why?
|
| Risk Factors | 2 | 2019 | 3537 | 0.050 |
Why?
|
| Hindlimb | 1 | 2001 | 57 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2014 | 93 | 0.050 |
Why?
|
| Indenes | 1 | 1980 | 1 | 0.050 |
Why?
|
| Thromboxane A2 | 1 | 2000 | 2 | 0.050 |
Why?
|
| Receptors, Prostaglandin | 1 | 2000 | 3 | 0.050 |
Why?
|
| Diuretics | 1 | 1980 | 22 | 0.050 |
Why?
|
| Platelet Aggregation | 1 | 2000 | 21 | 0.050 |
Why?
|
| Indans | 1 | 1980 | 25 | 0.050 |
Why?
|
| Opioid Peptides | 3 | 1984 | 28 | 0.040 |
Why?
|
| Supine Position | 1 | 2019 | 9 | 0.040 |
Why?
|
| Drug Interactions | 4 | 2000 | 80 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2019 | 21 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2000 | 97 | 0.040 |
Why?
|
| Neoplasms | 1 | 2006 | 611 | 0.040 |
Why?
|
| Brain Mapping | 3 | 1985 | 182 | 0.040 |
Why?
|
| Water Deprivation | 1 | 1999 | 1 | 0.040 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1999 | 2 | 0.040 |
Why?
|
| Protease Inhibitors | 2 | 2014 | 14 | 0.040 |
Why?
|
| Rats, Inbred BN | 2 | 2012 | 32 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2000 | 109 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 1995 | 85 | 0.040 |
Why?
|
| Peptides | 2 | 2008 | 118 | 0.040 |
Why?
|
| Creatinine | 1 | 2018 | 174 | 0.040 |
Why?
|
| United States | 2 | 2017 | 3632 | 0.040 |
Why?
|
| Histocytochemistry | 3 | 1986 | 30 | 0.040 |
Why?
|
| Cell Line | 3 | 2007 | 450 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2017 | 12 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 287 | 0.040 |
Why?
|
| Beta vulgaris | 1 | 2017 | 11 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2015 | 3101 | 0.040 |
Why?
|
| Physical Endurance | 1 | 2017 | 31 | 0.040 |
Why?
|
| Guanylate Cyclase | 1 | 2017 | 6 | 0.040 |
Why?
|
| Fetal Organ Maturity | 1 | 2016 | 7 | 0.040 |
Why?
|
| Kinetics | 2 | 2014 | 205 | 0.040 |
Why?
|
| Oxygen | 1 | 2017 | 139 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 1996 | 24 | 0.040 |
Why?
|
| Receptors, Cell Surface | 2 | 2006 | 72 | 0.040 |
Why?
|
| Immunochemistry | 2 | 1986 | 8 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 1996 | 13 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 34 | 0.030 |
Why?
|
| Natriuresis | 1 | 1995 | 4 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2015 | 3112 | 0.030 |
Why?
|
| Motor Neurons | 1 | 1996 | 53 | 0.030 |
Why?
|
| Neurons, Afferent | 1 | 1996 | 54 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 27 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 37 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 89 | 0.030 |
Why?
|
| Binding, Competitive | 4 | 2001 | 38 | 0.030 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 29 | 0.030 |
Why?
|
| Nitrite Reductases | 1 | 2014 | 3 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2014 | 10 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 115 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 84 | 0.030 |
Why?
|
| Thiophenes | 1 | 2014 | 21 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2014 | 37 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2014 | 46 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 279 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2014 | 65 | 0.030 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mercury Compounds | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chromatography, Agarose | 1 | 2014 | 3 | 0.030 |
Why?
|
| Neurotensin | 1 | 2014 | 5 | 0.030 |
Why?
|
| Atropine Derivatives | 2 | 1984 | 2 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2014 | 35 | 0.030 |
Why?
|
| Respiration | 2 | 1984 | 26 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 92 | 0.030 |
Why?
|
| Potassium | 2 | 1992 | 37 | 0.030 |
Why?
|
| Phenanthrolines | 1 | 2013 | 3 | 0.030 |
Why?
|
| p-Chloromercuribenzoic Acid | 1 | 2013 | 3 | 0.030 |
Why?
|
| Phenylmercuric Acetate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 38 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2014 | 90 | 0.030 |
Why?
|
| Edetic Acid | 1 | 2013 | 8 | 0.030 |
Why?
|
| Adiponectin | 1 | 2014 | 103 | 0.030 |
Why?
|
| Binding Sites | 3 | 1991 | 125 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 525 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2014 | 225 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 278 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 31 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 232 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 200 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 100 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2006 | 98 | 0.030 |
Why?
|
| Prostaglandins E | 2 | 1983 | 2 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 681 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2109 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2010 | 82 | 0.030 |
Why?
|
| Pediatrics | 1 | 2014 | 132 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1994 | 109 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 637 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 413 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 1688 | 0.030 |
Why?
|
| Middle Aged | 2 | 2017 | 10834 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 969 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 1119 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2015 | 1167 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1994 | 192 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 4 | 1991 | 158 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 15 | 0.020 |
Why?
|
| Acetophenones | 1 | 2010 | 2 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2010 | 4 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2010 | 17 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 337 | 0.020 |
Why?
|
| Glioma | 1 | 1991 | 133 | 0.020 |
Why?
|
| Area Postrema | 1 | 2009 | 1 | 0.020 |
Why?
|
| Olivary Nucleus | 1 | 2009 | 2 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 1306 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2009 | 21 | 0.020 |
Why?
|
| Asphyxia | 1 | 2009 | 6 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2009 | 16 | 0.020 |
Why?
|
| Alanine | 1 | 2009 | 27 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 50 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2009 | 36 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2009 | 35 | 0.020 |
Why?
|
| Prostaglandins F | 2 | 1991 | 3 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 58 | 0.020 |
Why?
|
| Miconazole | 1 | 2008 | 1 | 0.020 |
Why?
|
| Quinacrine | 1 | 2008 | 1 | 0.020 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2008 | 1 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 11 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2008 | 22 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2008 | 9 | 0.020 |
Why?
|
| Lipoprotein Lipase | 1 | 2008 | 14 | 0.020 |
Why?
|
| Axonal Transport | 1 | 1988 | 3 | 0.020 |
Why?
|
| Immune Sera | 2 | 2003 | 9 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2008 | 47 | 0.020 |
Why?
|
| Rabbits | 2 | 1985 | 185 | 0.020 |
Why?
|
| Reactive Nitrogen Species | 1 | 2007 | 5 | 0.020 |
Why?
|
| Denervation | 2 | 1990 | 13 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 2402 | 0.020 |
Why?
|
| Enzyme Activators | 1 | 2007 | 4 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 12 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2007 | 25 | 0.020 |
Why?
|
| Gadolinium | 1 | 2007 | 19 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 71 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1986 | 55 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2007 | 72 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 77 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 97 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 192 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2006 | 2 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 10 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 21 | 0.020 |
Why?
|
| Cell Shape | 1 | 2006 | 26 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2006 | 22 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 246 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 62 | 0.020 |
Why?
|
| Lateral Ventricles | 1 | 2005 | 2 | 0.020 |
Why?
|
| Animals, Congenic | 1 | 2006 | 14 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2006 | 23 | 0.020 |
Why?
|
| Computer Systems | 1 | 2005 | 12 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 139 | 0.020 |
Why?
|
| Heterozygote | 1 | 2006 | 52 | 0.020 |
Why?
|
| Tegmentum Mesencephali | 1 | 1985 | 1 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2006 | 100 | 0.020 |
Why?
|
| Acetylcholinesterase | 1 | 1985 | 17 | 0.020 |
Why?
|
| Base Sequence | 1 | 2006 | 240 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2005 | 61 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 350 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1985 | 45 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2005 | 118 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 1985 | 11 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1985 | 40 | 0.020 |
Why?
|
| Cats | 1 | 1985 | 105 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1995 | 73 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 1984 | 23 | 0.020 |
Why?
|
| Propranolol | 1 | 1984 | 16 | 0.020 |
Why?
|
| Melanocyte-Stimulating Hormones | 1 | 1984 | 2 | 0.020 |
Why?
|
| Naloxone | 1 | 1984 | 23 | 0.020 |
Why?
|
| Kidney Concentrating Ability | 1 | 1983 | 1 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1983 | 31 | 0.010 |
Why?
|
| Motor Activity | 1 | 1985 | 310 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1983 | 72 | 0.010 |
Why?
|
| Muridae | 1 | 1982 | 1 | 0.010 |
Why?
|
| Kallikreins | 1 | 1982 | 2 | 0.010 |
Why?
|
| Weaning | 1 | 1982 | 6 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 1982 | 14 | 0.010 |
Why?
|
| 1-Sarcosine-8-Isoleucine Angiotensin II | 2 | 1991 | 4 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 2001 | 9 | 0.010 |
Why?
|
| Aminopeptidases | 1 | 2000 | 3 | 0.010 |
Why?
|
| Microvilli | 1 | 2000 | 7 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2000 | 38 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2001 | 47 | 0.010 |
Why?
|
| Indomethacin | 1 | 1980 | 6 | 0.010 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2000 | 1 | 0.010 |
Why?
|
| Urination | 1 | 1980 | 15 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 2000 | 21 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 35 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1980 | 82 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 2000 | 29 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 97 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2000 | 114 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2000 | 147 | 0.010 |
Why?
|
| Macrophages | 1 | 2000 | 188 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1998 | 160 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1998 | 196 | 0.010 |
Why?
|
| Adult | 1 | 2008 | 8426 | 0.010 |
Why?
|
| Decerebrate State | 1 | 1993 | 1 | 0.010 |
Why?
|
| Aorta | 1 | 1993 | 103 | 0.010 |
Why?
|
| Swine | 1 | 1993 | 201 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1992 | 8 | 0.010 |
Why?
|
| Biotransformation | 1 | 1991 | 5 | 0.010 |
Why?
|
| Angiotensin III | 1 | 1991 | 2 | 0.010 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1991 | 7 | 0.010 |
Why?
|
| Cytosol | 1 | 1991 | 25 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1991 | 7 | 0.010 |
Why?
|
| Astrocytoma | 1 | 1991 | 30 | 0.010 |
Why?
|
| Glucose | 1 | 1991 | 163 | 0.010 |
Why?
|
| Sinus of Valsalva | 1 | 1990 | 2 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1989 | 4 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1989 | 21 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1989 | 72 | 0.010 |
Why?
|
| Hypoglossal Nerve | 1 | 1987 | 2 | 0.000 |
Why?
|
| Models, Biological | 1 | 1990 | 373 | 0.000 |
Why?
|
| Carbachol | 1 | 1985 | 7 | 0.000 |
Why?
|
| Stereotyped Behavior | 1 | 1985 | 14 | 0.000 |
Why?
|
| Aortic Coarctation | 1 | 1985 | 4 | 0.000 |
Why?
|
| Catheterization | 1 | 1985 | 58 | 0.000 |
Why?
|